D
+3
Rivian: Narrowing Losses, R2 Mass Production Imminent, Is Rivian's Dawn Approaching?
Successfully climbed out of the second quarter loss mire
+3RivianFinancial Analysis
Day One Biopharmaceuticals
DAWN21.5300.00% ( 0.000 )
Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines f...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 21.530
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 21.530
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Day One Biopharmaceuticals Analyst Rating
View MoreForecast & Rating
Apr 6, 2026Price forecast
$21.50-0.14%
Forecast & RatingHold
8analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- WorldPharmaceuticals · May 11 at 04:39 AM
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
- TradingView · Apr 23 at 08:03 AM
Day One Biopharmaceuticals Received Notice of Delisting
- Market Beat · Apr 20 at 12:59 PM
Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year High - What's Next?
- Unusual Whales · Apr 9 at 02:31 PM
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
- Tip Ranks · Apr 6 at 03:40 PM
JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)
- Market Beat · Mar 30 at 01:50 AM
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 20.3% in March
Posts
View MoreBullish vs. Bearish — Last 3 Months
130 followers · 0 opinions
▲Bullish50%
50%Bearish▼